Equities research analysts at B. Riley began coverage on shares of Inflarx (NASDAQ:IFRX) in a research report issued to clients and investors on Thursday, MarketBeat reports. The brokerage set a “buy” rating and a $40.00 price target on the stock. B. Riley’s price target suggests a potential upside of 70.21% from the company’s current price.
A number of other equities research analysts also recently commented on IFRX. BMO Capital Markets began coverage on Inflarx in a research report on Monday, December 4th. They issued an “outperform” rating and a $31.00 price objective for the company. Leerink Swann began coverage on shares of Inflarx in a report on Monday, December 4th. They set an “outperform” rating and a $31.00 target price for the company. Finally, JPMorgan Chase & Co. began coverage on shares of Inflarx in a report on Monday, December 4th. They set an “overweight” rating and a $30.00 target price for the company.
Shares of Inflarx (NASDAQ:IFRX) traded up $0.95 during midday trading on Thursday, reaching $23.50. 16,037 shares of the company’s stock traded hands, compared to its average volume of 39,897. Inflarx has a 1-year low of $14.47 and a 1-year high of $26.92.
ILLEGAL ACTIVITY WARNING: “Inflarx (IFRX) Receives New Coverage from Analysts at B. Riley” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/11/inflarx-ifrx-receives-new-coverage-from-analysts-at-b-riley.html.
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company’s primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases.
Receive News & Ratings for Inflarx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inflarx and related companies with MarketBeat.com's FREE daily email newsletter.